BCR-ABL Transcripts - CML  - Chronic Myeloid Leukemia

 
''Chronic myeloid leukemia (CML) is characterized by the presence of BCR-ABL1 fusion gene. In over 95% of CML patients, the typical BCR-ABL1 transcript subtypes are e13a2 (b2a2), e14a2 (b3a2) or expression of both simultaneously. Other less frequent transcript subtypes, such as e1a2, e2a2, e6a2, e19a2, e1a3, e13a3 and e14a3, have been sporadically reported.1 Different subtypes of BCR-ABL1 transcripts encode fusion proteins with different sizes that may lead to different disease phenotypes. The e13a2 and e14a2 transcripts encode P210 BCR-ABL1 proteins with slightly different sizes. Patients with the e14a2 transcript have a significantly higher platelet count than those with the e13a2 transcript.2, 3, 4 Patients with the e19a2 transcript, which encodes P230, often present with prominent neutrophilic maturation or thrombocytosis, whereas patients with the e1a2 transcript, which encodes P190, often present with monocytosis, absence of basophilia and a tendency to progress to lymphoid blast phase (BP).5, ""
Extract of Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia,  July 14, 2017, Blood Cancer journal

ARTICLES

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients
December 2019, ASH 2019

Deep Analysis of BCR-ABL Transcripts Predicts Tyrosine Kinase Inhibitor Response in CML
February 28, 2019, Cancer Therapy Advisor

An e13a2 Type of BCR-ABL Transcript  Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors               ​********
December 2017, ASH 2017

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
July 14, 2017, Blood Cancer journal

BCR-ABL Transcript Type Predicts Response and Survival Among Patients with CML
February 1, 2016,  ASH Clinical News

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
May 6, 2014, Leukemia

Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring
July 2, 2012, Hindawi
​
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
November 19, 2010, BMC Hematology

Dual transcription of b2a2 and b3a2 BCR–ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene
June 10, 2002, British Journal of  Haematology

​
​